J&J execs say new launches and label expansions will fuel 'above-market' growth through 2021

Like its peers, Johnson & Johnson faces pricing and biosim threats in the coming years. But thanks to new launches and label expansions for existing meds, the drugmaker believes it can continue to outperform rivals in pharmaceuticals, execs said on a conference call Thursday.